Patents Assigned to ACEA THERAPEUTICS, INC.
-
Publication number: 20230322668Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.Type: ApplicationFiled: June 15, 2023Publication date: October 12, 2023Applicant: ACEA Therapeutics, Inc.Inventors: Long Mao, Xiao Xu, Namir Shaabani, Can Jin
-
Patent number: 11753373Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.Type: GrantFiled: June 1, 2022Date of Patent: September 12, 2023Assignee: ACEA Therapeutics, Inc.Inventors: Long Mao, Xiao Xu, Namir Shaabani, Can Jin
-
Patent number: 11612602Abstract: The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.Type: GrantFiled: August 24, 2020Date of Patent: March 28, 2023Assignee: ACEA Therapeutics, Inc.Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
-
Patent number: 11498922Abstract: The present invention relates to methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.Type: GrantFiled: April 7, 2017Date of Patent: November 15, 2022Assignees: ACEA Therapeutics, Inc., Hangzhou ACEA Pharmaceutical Research Co., Ltd., Zhejiang ACEA Pharmaceuticals Co., Ltd.Inventors: Long Mao, Jia Liu, Yile Chen, Yuning Hua, Kongen Dai, Yimei Bao, Bojie Weng, Xi-aopeng Mo, Jian Wu, Xiao Xu, Wanhong Xu, Xiaobo Wang
-
Publication number: 20210309642Abstract: The invention relates to solid forms of certain N-(pyrimidinyloxy)acrylamide derivatives that are useful in the treatment of proliferation and immunological disorders and other diseases related to the dysregulation of kinases including EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK. The invention provides methods of making these materials and their salts and polymorphs, and intermediates for preparing these materials, as well as pharmaceutical compositions comprising these materials. The solid forms and pharmaceutical compositions comprising them are useful to treat conditions including a proliferation disorder, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye, rheumatoid arthritis, or lupus.Type: ApplicationFiled: August 9, 2018Publication date: October 7, 2021Applicants: ACEA Therapeutics, Inc., HANGZHOU ACEA PHARMACEUTICAL RESEARCH CO., LTD., ZHEJIANG ACEA PHARMACEUTICALS CO., LTD.Inventors: Long MAO, Jia LIU, Yile CHEN, Yuning HUA, Kunhua DONG, Liang CHEN, Bojie WENG, Xiaopeng MO, Kongen DAI, Yimei BAO, Jian WU, Bin LIANG, Guanglin ZHOU, Zhen WANG
-
Publication number: 20210300931Abstract: Disclosed methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC AND TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.Type: ApplicationFiled: April 7, 2017Publication date: September 30, 2021Applicants: ACEA Therapeutics, Inc., Hangzhou ACEA Pharmaceutical Research Co., Ltd., Zhejiang ACEA Pharmaceuticals Co., Ltd.Inventors: Long MAO, Jia LIU, Yile CHEN, Yuning HUA, Kongen DAI, Yimei BAO, Bojie WENG, Xi-aopeng MO, Jian WU, Xiao XU, Wanhong XU, Xiaobo WANG
-
Patent number: 11007197Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.Type: GrantFiled: September 30, 2019Date of Patent: May 18, 2021Assignee: ACEA THERAPEUTICS, INC.Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
-
Publication number: 20210100802Abstract: The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.Type: ApplicationFiled: August 24, 2020Publication date: April 8, 2021Applicant: ACEA Therapeutics, Inc.Inventors: Xiao XU, Xiaobo WANG, Long MAO, Li ZHAO, Biao XI
-
Patent number: 10799504Abstract: The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.Type: GrantFiled: January 12, 2013Date of Patent: October 13, 2020Assignee: ACEA THERAPEUTICS, INC.Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
-
Publication number: 20200129516Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.Type: ApplicationFiled: September 30, 2019Publication date: April 30, 2020Applicant: ACEA Therapeutics, Inc.Inventors: Xiao XU, Xiaobo WANG, Long MAO, Li ZHAO, Biao XI
-
Patent number: 10596174Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.Type: GrantFiled: February 17, 2017Date of Patent: March 24, 2020Assignee: ACEA THERAPEUTICS, INC.Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
-
Patent number: 10562918Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.Type: GrantFiled: January 29, 2018Date of Patent: February 18, 2020Assignee: ACEA THERAPEUTICS, INC.Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
-
Patent number: 10533011Abstract: Provided are methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.Type: GrantFiled: June 30, 2016Date of Patent: January 14, 2020Assignee: ACEA THERAPEUTICS, INC.Inventors: Long Mao, Jia Liu, Yile Chen, Yuning Hua, Kongen Dai, Yimei Bao, Bojie Weng, Xiaopeng Mo, Jian Wu, Xiao Xu, Wanhong Xu, Xiaobo Wang
-
Patent number: 10449196Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.Type: GrantFiled: September 18, 2017Date of Patent: October 22, 2019Assignee: ACEA Therapeutics, Inc.Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
-
Publication number: 20180312510Abstract: Provided are methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.Type: ApplicationFiled: June 30, 2016Publication date: November 1, 2018Applicant: ACEA THERAPEUTICS, INC.Inventors: Long MAO, Jia LIU, Yile CHEN, Yuning HUA, Kongen DAI, Yimei BAO, Bojie WENG, Xiaopeng MO, Jian WU, Xiao XU, Wanhong XU, Xiaobo WANG